Hematologic outcomes and exploratory pharmacogenetic associations in patients receiving docetaxel-containing chemotherapy: a retrospective study
Frontiers in Genetics · 17.11.2026 · 17
DOI: 10.3389/fgene.2026.1996630 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Genetics, online erschienen am 17.11.2026. Verfasst von Xue-Mei Tian und 7 weiteren Autor:innen. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Hematologic abnormalities are a clinical concern during docetaxel-containing chemotherapy. This study aimed to characterize paired hematologic changes and study-defined cytopenia and explore associations with candidate genetic variants.
Method
This retrospective study included 67 adults with solid tumors receiving docetaxel (70 mg/m 2 ) in combination regimens between June 2021 and March 2022. Measurements before and 3–10 days after an index cycle were compared using paired tests. Associations between 16 variants and five post-treatment hematologic outcomes were assessed using linear regression adjusted for baseline measurements and clinical covariates. Benjamini–Hochberg (BH) correction was applied separately to additive and alternative inheritance models.
Results
Mean white blood cell (WBC) count changed by −1.88 × 10 9 /L (95% confidence interval [CI], −2.53 to −1.23), and absolute neutrophil count (ANC) by −1.16 × 10 9 /L (95% CI, −1.77 to −0.55; both unadjusted P < 0.001). Study-defined grade 3–4 leukopenia and neutropenia were observed in 18 (26.9%) and 19 (28.4%) patients, respectively. Four of 80 primary additive tests had unadjusted P < 0.05, but none met BH q < 0.05 (minimum q = 0.666). For cytochrome P450 family one subfamily B member 1 (CYP1B1) rs1056836, adjusted post-treatment differences comparing GC/GG with CC were 1.21 × 10 9 /L for WBC (95% CI, 0.09 to 2.34; P = 0.036) and 1.08 × 10 9 /L for ANC (95% CI, 0.13 to 2.03; P = 0.027); both q values were 0.882.
Conclusion
Post-treatment WBC and ANC were lower than pretreatment values. Neither the primary additive analyses nor the evaluated alternative CYP1B1 models identified associations meeting the multiplicity-adjusted significance threshold.
Zitieren
APA
Tian, X., Lu, L., Yao, Y., Wang, Y., Xie, P., He, R., Wang, D., & Yang, Q. (2026). Hematologic outcomes and exploratory pharmacogenetic associations in patients receiving docetaxel-containing chemotherapy: a retrospective study. Frontiers in Genetics, 17. https://doi.org/10.3389/fgene.2026.1996630
Vancouver
Tian X, Lu L, Yao Y, Wang Y, Xie P, He R, et al. Hematologic outcomes and exploratory pharmacogenetic associations in patients receiving docetaxel-containing chemotherapy: a retrospective study. Frontiers in Genetics. 2026;17. doi:10.3389/fgene.2026.1996630
BibTeX
@article{Tian2026,
author = {Tian, Xue-Mei and Lu, Li-Shan and Yao, Yun-Chang and Wang, Yao and Xie, Pei-Tao and He, Ru-Pu and Wang, Dan and Yang, Qing},
title = {Hematologic outcomes and exploratory pharmacogenetic associations in patients receiving docetaxel-containing chemotherapy: a retrospective study},
journal = {Frontiers in Genetics},
year = {2026},
volume = {17},
doi = {10.3389/fgene.2026.1996630}
}
EUVIMED